Celgene Corporation (Celg) is a biopharmaceutical company that researches, develops, and commercializes medicines for the treatment of cancer and inflammatory diseases. Celgene’s stock is traded on the Nasdaq Global Select Market under the ticker symbol CELG. As one of the most well-known and successful biopharmaceutical companies in the world, Celgene’s stock performance has been closely watched by investors. In this article, we’ll take a look at Celg’s market watch overview, stock performance, financials, and investment outlook.
Celg Marketwatch Overview
Celgene Corporation is a global biopharmaceutical company that develops, manufactures, and commercializes medicines for the treatment of cancer and inflammatory diseases. The company is headquartered in Summit, New Jersey, and has operations in over 25 countries. Celgene’s stock is traded on the Nasdaq Global Select Market under the ticker symbol CELG.
Celg Stock Performance
Celgene’s stock has had a volatile history, with periods of strong growth followed by periods of decline. In the past year, the stock has increased steadily, reaching a high of $95.86 in March 2021. However, the stock has since dropped to a low of $78.68 in May 2021. Despite this, the stock is still up nearly 30% from its 52-week low of $60.89 in May 2020.
Celg Financials
Celgene has reported strong financial performance in recent quarters. For the first quarter of 2021, the company reported revenue of $4.1 billion, an increase of 14% from the same period in 2020. Net income for the quarter was $1.2 billion, an increase of 42% from the same period in 2020. The company also reported a strong balance sheet, with total assets of $30.5 billion and total liabilities of $16.1 billion.
Celg Investment Outlook
Celgene’s strong financial performance and promising pipeline of new treatments make it a strong long-term investment. Analysts expect the stock to continue to grow in the coming months, as the company continues to develop new treatments and expand its business. In addition, Celgene’s recent merger with BMS has opened up new opportunities for growth and expansion.
Celgene Corporation is an established and successful biopharmaceutical company with a promising future. The company’s strong financials and promising pipeline of treatments make it a strong long-
